Golub M S, Thananopavarn C, Eggena P, Barrett J D, Sambhi M P
Chest. 1983 Feb;83(2 Suppl):377-9. doi: 10.1378/chest.83.2_supplement.377.
Two studies of the responses to clonidine as the sole antihypertensive drug in the treatment of mild-to-moderate hypertension are reported. In the first, 11 patients with mild hypertension were treated with 0.1 mg clonidine twice daily for eight weeks. Those patients with "low renin" hypertension (n = 7) were noted to show an increase in plasma renin activity; the patients with "normal renin" hypertension (n = 4) tended to show a decrease. Both groups had a similar decrease in blood pressure. The changes in renin activity correlated significantly (p less than 0.01) with the small changes in endogenous creatinine clearance (r = 0.84). In the second study, 16 patients with mild-to-moderate essential hypertension were treated for three months with 0.2 mg clonidine three times daily. Blood pressure decreased from 167 +/- 4/105 +/- 2 to 140 +/- 3/90 +/- 2 mm Hg (p less than 0.01). Blood pressure changes correlated with decreases in plasma catecholamines (r = 0.61, p less than 0.001) and heart rate (r = 0.78, p less than 0.001). No significant changes in cardiac output, blood volume, renal blood flow, or glomerular filtration rate were noted. Clonidine is an effective and safe therapy when used as the sole medication in treating mild-to-moderate hypertension.
报道了两项关于可乐定作为单一抗高血压药物治疗轻至中度高血压反应的研究。第一项研究中，11例轻度高血压患者每日两次服用0.1mg可乐定，持续8周。发现那些“低肾素”高血压患者（n = 7）血浆肾素活性增加；“正常肾素”高血压患者（n = 4）则倾向于降低。两组血压下降相似。肾素活性变化与内生肌酐清除率的微小变化显著相关（p < 0.01）（r = 0.84）。第二项研究中，16例轻至中度原发性高血压患者每日三次服用0.2mg可乐定，治疗三个月。血压从167±4/105±2降至140±3/90±2mmHg（p < 0.01）。血压变化与血浆儿茶酚胺降低（r = 0.61，p < 0.001）和心率降低（r = 0.78，p < 0.001）相关。未观察到心输出量、血容量、肾血流量或肾小球滤过率有显著变化。可乐定作为单一药物用于治疗轻至中度高血压时是一种有效且安全的疗法。
